Member Info for Yorkshirepragma

Sorry to hear that....as an old bold bio bod...can I Then suggest that this co is likely to succeed under a highly competent team .The products and application are being well recognised . Hence theHigh profile investment interest.
Good karma...

T’imiter, agreed , and why not with potential testing alone being capable of producing xx million month rev. And one of Warren Buffett’s chosen post retirement options as an investment taker.
QED
GLA

Is that the same that manages Apple ,Google ....yup....thatlll do for us

Huge potential to be had with testing alone ...Cytiva delivery imminent. What’s more to be Had. Buys exceeding sells too...market again.

I suspect that’s a very insightful comment.

https://www.statista.com/statistics/1104645/covid19-testing-rate-select-countries-worldwide/

Millions of tests needed..TW? Knowledgeable? Capable? Not worth listening to...

TW must be delusional. 60,000 pass3d away in the UK alone....foolishness.

Clearly Cytive are very near completion of suitable LFD.

https://mobile.twitter.com/MylesMcNulty/status/1270315302920863744
Inside track perhaps? But presumably based on unit test volume.

MM SuggestIon of av $15m /month Adeptrix revenue stream , gives (@ conservative x5 earnings val.) a MK of ca 0.75 bn. ...
x2 current.
That’s before the rest. An emerging company with a likely consistent revenue...a rare thing these days.
GLA

AS will no doubt wish to manage the information flow this week .
No BOD leaves it floating.
-Cytiva info shortly ...

1.Hold your a Avacta. Take a profit when the next phase of rise comes about , (which it will on future announcements).
2. Put an amount into Terry Smiths global fund...7% up in 2020 After markets have moved recently with Covid.
DYOR GL

RK,See recent Pharma article AQ article ....one things for sure there’s a lot of activity out there! Bodes well for something in the future... my money would be on the Danaher team possibly if all goes well.
Cheers
https://www.pharmasalmanac.com/articles/ma-fundamental-to-pharma-industry-growth

If the revenues begin to flow from testing ...then £Xm per annum rev will soon create a significant company. Any T/O pharma will likely move early to obviate a high purchase price.
AS cognisant of this and has bought a strong position from last weeks well advised raise...good move.
All getting very interesting to say the least.

...and the correct wording is required ....could be the/ an interested party . If a company is moving Forward ,then the accelerator may be pressed.

RK,

Very well said, and agree the BODs motivation will be there for future.

For a balanced discussion on 2nd Wave see Prof Spector webcast below...

https://m.youtube.com/watch?v=oAmVPaxMQ1c

One things for sure there will be news soonest...AS promise...
Regards

RK. Takeovers been ‘presented‘ on a few occasions here, and also within MylescMc Papers. It’ll be interesting to see what his upcoming pt3 update suggests.
I suspect the ‘flags are up’ on Avacta for a few, and with current significant pressures
It may happen quicker than many might Anticipate. Early bird etc.. There are several suspects...
I’ll be watching Alistair Smiths eye movement direction in future interviews for a clue if the question is put to him on TO.
GLA

Prediction:
End 20 - £1-2bn (higher subject to test revenue.)
Mid 21 - Bought for 2-3bn ( again higher subject to test revenue)
GLA

Jonesy...here’s hoping ...the CEOs description of the potential Revenues from ‘testing’ + the comments on test quality for Adeptrix speak volumes...
Bon weekend
GLA

Mr Blair advertising now!